Filing Flows

Filing Flows › Ovid Therapeutics (OVID) › Next earnings date

Ovid Therapeutics (OVID) earnings on Nov 11, 2026: what to expect

Ovid Therapeutics (OVID) is expected to report earnings on Nov 11, 2026 (estimated), in 3 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.08 (−$0.10 to −$0.05, 9 estimates) on revenue of $26K, against −$0.17 and $132K a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 66% chance of beating next time.

Report dateNov 11, 2026 (estimated)
Days to go3
EPS estimate−$0.08
Revenue estimate$26K
Beat rate50%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Ovid Therapeutics: revenue lines, growth year over year, Q2 2026Ovid Therapeutics: revenue lines, growth year over year, Q2 2026Revenue-88%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.17 on revenue of $68K, against the analysts' −$0.08.

The last report

Ovid Therapeutics reported revenue of $733K for the second quarter 2026 (-88% Y/Y), net loss $15.0M. How it makes money → · Every quarter →

Ovid Therapeutics: EPS against the estimate, last 4 reportsOvid Therapeutics: EPS against the estimate, last 4 reportsEstimateReported−$0.15−$0.17Nov 25−$0.10$0.06Mar 26−$0.11−$0.12May 26−$0.10−$0.08Aug 26
Latest (Aug 26): Estimate −$0.10, Reported −$0.08.

Ovid Therapeutics' latest quarter

Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.

Questions

When does OVID report earnings?

Ovid Therapeutics is expected to report on Nov 11, 2026 (estimated).

What are analysts expecting from Ovid Therapeutics?

EPS of −$0.08 and revenue of $26K for the quarter.

Does Ovid Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 50% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.